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Abstract
Background—Robotic surgery has been widely adopted for radical prostatectomy. We
hypothesize that this change is rapidly shifting procedures away from hospitals that do not offer
robotics and consequently increasing patient travel.
Methods—A population-based observational study of all prostatectomies for cancer in NY, NJ,
and PA from 2000–2009 was performed using hospital discharge data. Hospital procedure volume
was defined as the number of prostatectomies performed for cancer in a given year. Straight-line
travel distance to treating hospital was calculated for each case. Hospitals were contacted to
determine year of acquisition of first robot.
Results—From 2000–2009, the total number of prostatectomies performed annually increased
substantially. The increase occurred almost entirely at the very high volume centers (≥106
prostatectomies/year). The number of hospitals performing prostatectomy fell 37% from 2000–
2009. By 2009, the 9% (21/244) of hospitals that had very high volume performed 57% of all
prostatectomies, and the 35% (86/244) of hospitals with a robot performed 85% of all
prostatectomies. Median travel increased 54% from 2000–2009, p<0.001. The proportion of
patients traveling ≥15 miles increased from 24% to 40%, p<0.001.
Conclusions—Over the past decade, the number of radical prostatectomies performed has risen
substantially. These procedures have been increasingly centralized at high volume centers, leading
to longer patient travel distances. Few prostatectomies are now performed at hospitals that do not
offer robotic surgery. Future work should focus on the impact of these trends on cancer control,
functional outcomes, access to care and cost.
In 2000, the Food and Drug Administration first approved a robotic surgery system for use
for laparoscopic abdominal and pelvic procedures. Since then, robotic surgery has become
increasingly widely adopted. According to the exclusive manufacturer, >1000 robots have
been distributed in the US.1 The first descriptions of robotic-assisted laparoscopic
prostatectomy (RALP) were published in 2001.2–4 Subsequent studies have detailed the
safety and potential advantages of RALP, and preliminary data suggest that RALP has
rapidly become the most common approach to prostatectomy.5–11
There has been a simultaneous trend toward centralization of complex cancer procedures at
high volume centers.12 In response to studies documenting an association between hospital
procedure volume and clinical outcomes, many have advocated centralization of procedures,
such as prostatectomy, at high volume centers.13–24 Recent studies document that practice
patterns for some oncologic procedures are changing in response to these findings.12 This is
particularly true for relatively uncommon cancers that require complex extirpative
procedures, such as esophageal and pancreatic cancer. As these procedures have become
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centralized, the distances that patients travel for surgery have increased substantially.25 The
degree to which centralization has occurred for prostate cancer is unknown. While
prostatectomy is a complex procedure, prostate cancer is far more common than esophageal
or pancreatic cancer, so the extent and impact of centralization may be different.
This study evaluates how practice patterns have changed in the face of simultaneous trends
toward increasing use of RALP and increasing centralization of cancer surgery. We
hypothesize that over the past decade, prostatectomies have been centralized at higher
volume centers that offer robotic surgery, resulting in a relevant increase in travel for
patients seeking prostate cancer care.
Methods
A secondary data analysis was performed using inpatient discharge data from New Jersey
(NJ), New York (NY), and Pennsylvania (PA). Each state mandates reporting of claims
from all non-federal hospitals. Databay Resources (Warrendale, PA) acquires the de-
identified data from individual state agencies (State of NJ Department of Health and Senior
Services, State of NY Statewide Planning and Research Cooperative System, PA Healthcare
Cost Containment Council) and produces a database suitable for secondary analysis.
Available variables include demographic information, diagnosis codes (ICD-9), procedure
codes (ICD-9), length of stay, disposition at discharge, and hospital charges. The study was
exempted from full review and approved by the Institutional Review Boards of the
University of North Carolina and Fox Chase Cancer Center.
Men ≥ 18 years of age undergoing radical prostatectomy in the study area from 2000–2009
were included. Patients residing in the study area who underwent surgery outside of the
study area were not captured; however, patients residing outside the study area who had
surgery in the study area (inward border crossers) were included. All admissions with an
ICD-9 procedure code for radical prostatectomy (60.5) and a diagnosis code for prostate
cancer (185) were captured. Since there are no ICD-9 procedure codes specific for RALP or
laparoscopic prostatectomy, these procedures could not be differentiated from open
prostatectomy.
Patients were geocoded to zip code centroid, which was available for every case, using a
publicly available geocoding tool (Excel geocoding tool v2, Juice Analytics, Herndon, VA
referencing Yahoo! Maps Web Services - Geocoding API, Yahoo, Sunnyvale, CA).
Hospitals were geocoded to street address. Great-circle distance, a proven proxy for travel
time, was calculated between cases and the hospitals where the procedures were performed
[d = acos(sin(lat1).sin(lat2)+cos(lat1).cos(lat2).cos(long2−long1)).R].26–28 Inward border
crossers were excluded from the distance analyses. The mean travel distance for this group
(≈4% of total population) was >500 miles, and inclusion of this small, distinct group would
have disproportionately influenced the results.
Hospital procedure volume was calculated for each year individually. Since standard volume
cutpoints do not exist for prostatectomy, previously defined methodology for defining
hospital volume categories was used.25, 29 Five equal-sized groups of patients treated in
2000 were created based on procedure volume of the treating hospital. These quintiles were
designated very low, low, medium, high, and very high volume. These baseline 2000
volume cutpoints were then applied to each subsequent year to determine changes in the
distribution of patients amongst volume categories over time.
Hospitals in the study area that owned a robot in 2009 were identified through
communication with the exclusive vendor (Intuitive Surgical, Inc., Sunnyvale, CA). To add
depth to the analysis, each hospital was contacted directly to determine the year of
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acquisition of the first robot at the facility. This information was successfully obtained for
every hospital identified by the vendor as owning a robot in 2009. Lowess smoothers, fit
separately for hospitals that eventually obtained robots and those that did not, were used.30
For hospitals that eventually obtained robots, time was measured as years from robot
acquisition. Negative values indicate years before acquisition and positive values indicate
years after acquisition. For hospitals that never obtained robots, time was set as time from
2005, the midpoint of the study period. Multiple linear regression of procedure volume was
used for hypothesis testing of time trends. To account for the correlation of observations
within hospitals over time, we estimated the models using Generalized Estimating Equations
assuming an autoregressive (order 1) working correlation structure.31 The model included
covariates for years from baseline, whether the hospital ever acquired a robot, whether the
hospital had a robot in a given year, and interactions between the robot variables and years
from baseline. STATA version 10 (StataCorp, College Station, TX) was used to create
Figure 2 and for all statistical analyses. For Figure 4, all hospitals with robots in 2010 as
reported by the vendor were geocoded to zip code centroid and mapped.32
Results
108,112 prostatectomies met inclusion criteria. The total number of prostatectomies
performed annually increased substantially from 8,115 in 2000 to 10,241 in 2009. Figure 1a.
There was no significant change in the age or racial distribution of patients undergoing
prostatectomy over time. All of the increase in prostatectomy volume occurred at high
volume centers. The odds of surgery at a very high volume center increased more than six-
fold (OR 6.04; 95% CI 5.74, 6.37) over the study period. Both the total number and
proportion of cases performed at hospitals in lower volume categories declined over time. At
any given time, there were 590–600 non-federal acute care hospitals operating in the study
area. Of these, 462 performed ≥1 eligible case during the study period, but the annual
number of hospitals performing prostatectomy steadily decreased from 390 in 2000 to 244 in
2009 (37% decrease). Figure 1b. In 2000, the majority (242/390; 62%) of hospitals
performing prostatectomy were very low volume (1–15/yr) and accounted for only 19%
(1,567/8,115) of prostatectomies in the study area. Meanwhile only 8 of the 390 hospitals
(2%) met criteria as very high volume centers (≥106/yr), accounting for 20% (1,631/8,115)
of procedures. By 2009, the majority (145/244; 59%) of hospitals performing prostatectomy
remained very low volume (1–15/yr) but accounted for only 8% (845/10,241) of all
procedures The number of very high volume centers (≥106/yr) had grown to 21 out of 244
(9%), and these centers now performed the majority (5,828/10,241; 57%) of prostatectomies
in the study area.
Only one of the 462 hospitals that performed a prostatectomy during the study period had a
robot at the start of 2000, but by 2009, 18.6% of these hospitals had acquired a robot. In
2009, 11.0% of very low volume centers (1–15/yr), 37.0% of low volume centers (16–29/
yr), 59.1% of medium volume centers (30–53/yr), 89.7% of high volume centers (54–105/
yr), and 100.0% of very high volume centers (≥106/yr) owned a robot. In total, 35.3%
(86/244) of the hospitals performing prostatectomy had a robot in 2009, and these centers
performed 84.6% (8,662/10,241) of prostatectomies in the study area.
The mean prostatectomy volume for hospitals that never obtained a robot was 10.2/yr (SD
14.9) in 2000. For these hospitals, the mean volume decreased by 0.7/yr annually over the
study period (95%CI −0.8 to −;0.5). Figure 2. In contrast, the mean procedure volume for
hospitals that eventually obtained a robot was 48.4/yr (SD 59.8) in 2000. Prior to robot
acquisition, there was a trend toward gradually increasing procedure volume at hospitals that
eventually acquired a robot: mean 1.3/yr annual increase (95%CI −0.8 to 3.4). During the
year of robot acquisition, there was a ramping up phase with average hospital volume
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increasing by 8.5/yr (95%CI 3.9–13.0) above historical trends. After robot acquisition,
volume increased even more rapidly: mean 12.4/yr increase (95%CI 5.4–19.4) continuing
annually.
Median travel distance was proportional to hospital prostatectomy volume. Figure 3. This
relationship persisted throughout the study period. As a result, median travel for
prostatectomy increased 54% from 6.9 miles in 2000 to 10.6 miles in 2009. The proportion
of patients traveling ≥15 miles increased from 24% in 2000 to 40% in 2009, p<0.001.
Discussion
Two major forces have altered patterns of care for prostate cancer surgery over the past
decade. Since high surgical volumes have been associated with improved cancer control and
lower rates of morbidity and mortality following radical prostatectomy, many have
advocated centralization of prostatectomies at higher volume centers.15–22, 24, 29 During the
same time period, there has been rapid diffusion of RALP. First described about a decade
ago, RALP has quickly emerged as the most common technique for radical prostatectomy.33
Between 2003 and 2006–7, the use of RALP increased almost fivefold in the Medicare
population (9.2% vs. 43% of all prostatectomies).34 This study highlights how these changes
are impacting prostate cancer care on the patient, hospital, and population level.
The number of radical prostatectomies performed annually has increased over the past
decade and in particular over the past five years. Meanwhile, prostatectomies have been
progressively centralized at high volume centers. Unlike other cancers for which
centralization of extirpative procedures has occurred steadily over time, there was little
centralization of prostatectomy evident until the publication of the first major studies
advocating RALP. 25, 35–37 Beginning in 2004–2005, a rapid shift to higher volume centers
ensued. Within 3 years, few prostatectomies were performed at centers without robotic
surgery capabilities. The overall result has been sudden, population-wide, technology-driven
centralization of procedures that is without precedent.
The interplay of these trends is supported by the fact that acquisition of a robot led to a rapid
increase in the number of prostatectomies performed at a given hospital and that hospitals
that did not acquire a robot performed fewer prostatectomies over time. Still, a few hospitals
remain in the low volume categories for prostatectomy despite robot acquisition, suggesting
that volume is a dynamic influenced by the complex interplay between hospitals and
professional staff, where uptake of robotic techniques requires both hospital investment in
technology and the presence of surgeons able to perform the procedures.
On a population-level, rapid centralization has been an unintended, but potentially
beneficial, consequence of the introduction of robotics. Still, the full impact of the
introduction and uptake of RALP on the triad of quality, cost, and access needs to be
explored. Since publication of initial studies, RALP has been heavily marketed to patients,
surgeons, and hospitals as an attractive alternative to traditional open prostatectomy with the
promise of shorter hospitalization, faster recovery and minimal blood loss. However,
observational studies have also suggested that patients may have higher rates of
complications, such as incontinence and erectile dysfunction, following minimally invasive
prostatectomies.34, 38 One study found patients undergoing RALP had greater dissatisfaction
and regret with their treatment decision compared to patients who underwent open
prostatectomy, likely due to heightened expectations and subsequent disappointment with
this “innovative” technology.39 In addition, there is a steep learning curve for surgeons who
had been trained to perform traditional open procedures.40–41 The impact of the early end of
this learning curve on population-level cancer control and functional outcomes is not known.
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It is possible that the improvements in quality resultant from centralization could be offset,
at least in part, by the higher complication rate associated with RALP, particularly early in
the learning curve. The reported experience of surgeons at large referral centers supports the
theory that outcomes improve with increased surgical experience.15, 40–43 Ultimately,
however, no studies to date demonstrate that RALP, even in experienced hands, leads to
improved overall cancer control or functional outcomes compared to open prostatectomy.
The economic impact of the rapid diffusion of RALP also deserves consideration. The high
upfront capital investment associated with robot acquisition ($1.2–1.7+ million), annual
maintenance contracts ($150,000+/robot), and disposable instruments results in much
greater direct costs compared to open prostatectomy.44–46 Given diagnosis-based
reimbursement in the U.S., most hospitals receive little or no additional payment to offset
these added costs. Many hospitals have marketed robotic surgery heavily to patients, likely
in an effort to recoup the fixed capital investment costs of robot acquisition and
maintenance, which may be amortized over a given volume of cases. This revenue shift
places an additional burden on the health care system in exchange for potential yet
incalculable societal benefits of more rapid convalescence and centralized care.
Many investigators have attempted to quantify the additional costs of this technology. In an
early study, Lotan et al. optimistically assumed a utilization rate of 300 cases/year (far in
excess of our upper quintile) and estimated the cost of RALP to be ≈$2500 more per case
than open prostatectomy ($857/case for the robot + $1705/case for disposable
instruments).46 Another analysis found the “break even” point for RALP versus open
prostatectomy was between 10 and 15 cases/week, again well above hospital volumes in this
study where only 2.9% of hospitals (7/244) performed >300 prostatectomies in 2009.45
Another group of investigators estimated an increase of $2315 in median direct costs for
RALP compared to open prostatectomy due to additional surgical supply and OR costs.
After adding the additional fixed costs of the robot, the total additional cost burden of RALP
increased to $4713/case assuming an average of 126 cases/year.46 There is additional cost
associated with the learning curve but this is difficult to quantify since the number of RALP
each surgeon must complete to be competent varies widely.41 Based on eight published
series, one group estimated the average learning curve was 77 cases, resulting in $217,034
additional operating room and anesthesia costs.47 Given that published studies have not
demonstrated superior oncologic and functional outcomes for RALP over an open approach,
many hospitals, insurers and federal agencies question both the comparative effectiveness
and the cost effectiveness of this new technology.38, 46, 48 Understanding the extent to which
individual and societal benefits may offset the indisputable direct cost disadvantages of
RALP requires additional study. With >1000 robotic surgical systems installed in the past
decade in the U.S., the scale of these economic considerations is considerable.
The impact of RALP and centralization on geographic access to care for prostate cancer has
not been previously examined. In this study, the distance patients traveled to reach the
treating hospital increased > 50% over the study period. This is consistent with previous
work demonstrating that informal centralization results in increased patient travel.25 With
market-driven centralization in the U.S., universal patient access is only a minor determinant
of the geographic location of high volume centers. Consequently, the geographic distribution
of high volume centers and robots is not necessarily optimized for patient travel and access
to care. Figure 4. While the absolute increase in median straight-line travel distance was
only 3.7 miles, it is important to remember that straight-line distance underestimates actual
road mileage by 20–40%.25, 28, 49 This increase in travel is particularly remarkable
considering the study area is a densely populated region with extensive healthcare resources
and relatively few rural counties. As a result, findings from this region likely underestimate
the impact of centralization on patient travel burden nationwide.
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In previous studies, we have demonstrated that patterns of centralization occurring in this
region are similar to those seen nationwide.12, 25 Similarly, the uptake of robotics is not
unique to this region, but is occurring nationally. Figure 4. Still, trends in this region may
not completely represent practice patterns across the country. For example, <10% of our
study population lived in rural counties, so this study may underestimate the impact of
centralization on travel distance and overestimate the availability of prostate cancer care for
patients from more rural areas of the country.
Another major limitation of hospital discharge data is the lack of detailed case information.
For example, while we examine the influence of robot acquisition, we do not know the
proportion of prostatectomies at a hospital with a robot that are actually performed
robotically. Additional information about the hospitals (i.e. teaching status, ownership, etc.)
and the patients (i.e. comorbidity, cancer staging, etc.) would greatly enhance our analysis
but were not available. In particular, without information on tumor stage, Gleason score,
PSA, and other factors used to risk stratify cancer patients, we were not able to determine if
the disease severity of patients treated with prostatectomy changed over time.
Similarly, we were not able to examine how centralization, the introduction of robotics, and
travel influenced the relative frequency with which surgery, active surveillance, and
radiation therapy were used to treat localized disease. Prostate cancer differs from other
cancers to the extent that surgical therapy is not the clear “gold standard,” but rather one
among several equivalently appropriate treatment options. The vast majority of men
diagnosed with prostate cancer in the U.S. during the study period had clinically localized
disease.50 For these men, surgery, radiation therapy and, in some cases, active surveillance
are all considered acceptable treatment options.51 The perception that RALP was associated
with quicker recovery or fewer side effects may have led patients with indolent disease, who
previously would have chosen active surveillance, to proceed with surgery. These behavioral
economics issues are important and deserve attention in future studies.
Conclusions
Over the past decade, there has been widespread adoption of RALP and increasing
centralization of prostate cancer surgery at high volume centers. These changes have had a
major impact on patterns of care for prostate cancer. On a population-level, the number of
radical prostatectomies performed has risen substantially, but the true impact on patient level
outcomes is unknown. Future studies should focus on the impact of these trends on access to
care and cost, in addition to cancer control and functional outcomes.
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Figure 1a. Total number of prostatectomies performed annually in NJ, NY, and PA, 2000–
2009.
Figure 1b. Total number of hospitals performing prostatectomy each year in NJ, NY, and
PA, 2000–2009. During this time period, there were roughly 590–600 acute care hospitals in
the study area.
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Relationship between hospital prostatectomy volume and robot acquisition.
Each dot represents a single hospital in a single year. Hospitals that acquired a robot during
the study period are red. Those that never obtained a robot are blue. For the hospitals that
acquired a robot, year 0 is the year that the robot was acquired. For the hospitals that never
acquired a robot, year 2005 (midway through the study period) was designated as year 0.
The fitted curves show the trends in prostatectomy volume.
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Median distance traveled in miles from patient home to hospital where prostatectomy was
performed.
Stitzenberg et al. Page 13














Figure 4a. Geographic location, by zip code, of US hospitals with robots in 2010. (Not
shown: There are two hospitals with robots in Alaska, both in the same zip code in
Anchorage. There are two hospitals with robots in Hawaii, both in Honolulu but in different
zip codes.)
Figure 4b. Geographic location, by zip code of hospitals with robots in NJ, NY, and PA in
2010.
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